LU90987I2 - Copaxone et ses dérivés pharmaceutiquement acceptables - Google Patents

Copaxone et ses dérivés pharmaceutiquement acceptables

Info

Publication number
LU90987I2
LU90987I2 LU90987C LU90987C LU90987I2 LU 90987 I2 LU90987 I2 LU 90987I2 LU 90987 C LU90987 C LU 90987C LU 90987 C LU90987 C LU 90987C LU 90987 I2 LU90987 I2 LU 90987I2
Authority
LU
Luxembourg
Prior art keywords
copaxone
pharmaceutically acceptable
acceptable derivatives
copolymer
kilodaltons
Prior art date
Application number
LU90987C
Other languages
English (en)
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26939072&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=LU90987(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of LU90987I2 publication Critical patent/LU90987I2/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/74—Synthetic polymeric materials
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G69/00—Macromolecular compounds obtained by reactions forming a carboxylic amide link in the main chain of the macromolecule
    • C08G69/02—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids
    • C08G69/08—Polyamides derived from amino-carboxylic acids or from polyamines and polycarboxylic acids derived from amino-carboxylic acids
    • C08G69/10—Alpha-amino-carboxylic acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Genetics & Genomics (AREA)
  • Toxicology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Rehabilitation Therapy (AREA)
  • Molecular Biology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Polymers & Plastics (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Polyamides (AREA)
LU90987C 1994-05-24 2002-08-05 Copaxone et ses dérivés pharmaceutiquement acceptables LU90987I2 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US24803794A 1994-05-24 1994-05-24
US34424894A 1994-11-23 1994-11-23
PCT/US1995/006551 WO1995031990A1 (fr) 1994-05-24 1995-05-23 Ameliorations apportees a des compositions de copolymeres contenant du copolymere-1

Publications (1)

Publication Number Publication Date
LU90987I2 true LU90987I2 (fr) 2003-02-25

Family

ID=26939072

Family Applications (1)

Application Number Title Priority Date Filing Date
LU90987C LU90987I2 (fr) 1994-05-24 2002-08-05 Copaxone et ses dérivés pharmaceutiquement acceptables

Country Status (30)

Country Link
US (11) US5800808A (fr)
EP (1) EP0762888B1 (fr)
JP (2) JPH10500955A (fr)
KR (1) KR100403750B1 (fr)
CN (2) CN1310673C (fr)
AT (1) ATE212857T1 (fr)
AU (1) AU2602195A (fr)
BR (2) BR9507758A (fr)
CA (1) CA2191088C (fr)
CZ (1) CZ292247B6 (fr)
DE (2) DE10299030I1 (fr)
DK (1) DK0762888T3 (fr)
EE (1) EE03423B1 (fr)
ES (1) ES2172586T3 (fr)
FI (1) FI120236B (fr)
GE (1) GEP20002205B (fr)
HU (1) HU223473B1 (fr)
IL (2) IL113812A (fr)
LU (1) LU90987I2 (fr)
MD (1) MD1443G2 (fr)
NL (1) NL300096I2 (fr)
NO (1) NO324528B1 (fr)
NZ (1) NZ287335A (fr)
PL (1) PL181026B1 (fr)
PT (1) PT762888E (fr)
SI (1) SI0762888T1 (fr)
SK (1) SK283699B6 (fr)
TJ (1) TJ392B (fr)
UA (1) UA62908C2 (fr)
WO (1) WO1995031990A1 (fr)

Families Citing this family (130)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5858980A (en) * 1990-03-30 1999-01-12 Autoimmune, Inc. Peptide fragments of myelin basic protein
US7090982B2 (en) 1991-10-22 2006-08-15 The Governors Of The University Of Alberta Methods of predicting therapeutic efficacy of treatment of a multiple sclerosis patient
US6252040B1 (en) 1991-10-22 2001-06-26 The Governors Of The University Of Alberta Peptide specificity of anti-myelin basic protein and the administration of myelin basic protein peptides to multiple sclerosis patients
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US5858964A (en) * 1995-04-14 1999-01-12 Yeda Research And Development Co. Ltd. Pharmaceutical compositions comprising synthetic peptide copolymer for prevention of GVHD
IL119989A0 (en) * 1997-01-10 1997-04-15 Yeda Res & Dev Pharmaceutical compositions for oral treatment of multiple sclerosis
AU2868699A (en) * 1998-02-13 1999-08-30 Autoimmune, Inc. Treatment of multiple sclerosis using cop-1 and th2-enhancing cytokines
ES2527760T3 (es) * 1998-07-23 2015-01-29 Yeda Research And Development Co., Ltd. Tratamiento de enfermedad de Crohn con copolímero 1 y polipéptidos
IL141021A0 (en) 1998-07-23 2002-02-10 Yeda Res & Dev Treatment of autoimmune conditions with copolymer 1 and related copolymers
CA2336238A1 (fr) 1998-07-23 2000-02-03 The President And Fellows Of Harvard College Peptides synthetiques et procedes d'utilisation de ceux-ci dans des therapies de maladies auto-immunes
US6514938B1 (en) 1998-09-25 2003-02-04 Yeda Research And Development Co. Ltd. At The Weizmann Institute Of Science Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
HU229719B1 (en) 1998-09-25 2014-05-28 Yeda Res & Dev Copolymer-1-delated polipeptides for use as molecular weight markers and for therapeutic use
US6800287B2 (en) 1998-09-25 2004-10-05 Yeda Research And Development Co., Ltd. Copolymer 1 related polypeptides for use as molecular weight markers and for therapeutic use
WO2000020010A1 (fr) * 1998-10-02 2000-04-13 Yeda Research And Development Co., Ltd. Administration en jours alternes de copolymer 1 destine au traitement de maladies autoimmunes
US7083777B1 (en) 1999-04-02 2006-08-01 The Brigham And Women's Hospital, Inc. Immunomodulating polymers
ATE302020T1 (de) * 2000-01-20 2005-09-15 Yeda Res & Dev Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
ZA200206457B (en) * 2000-02-18 2003-08-13 Yeda Res & Dev Oral, nasal and pulmonary dosage formulations of copolymer 1.
EP1261361B1 (fr) * 2000-02-18 2006-06-14 Yeda Research And Development Company, Ltd. Formes posologiques a administration par voie orale, nasale et pulmonaire du copolymere 1 (acetate de glatiramer)
IL153236A0 (en) * 2000-06-05 2003-07-06 Teva Pharma The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
US20020077278A1 (en) * 2000-06-05 2002-06-20 Yong V. Wee Use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
ES2256200T3 (es) * 2000-06-07 2006-07-16 Yeda Research And Development Co., Ltd. El uso de copolimero 1 y peptidos y polipeptidos relacionados, y de celulas t tratadas con los mismos, para neuroproteccion frente a la toxicidad del glutamato.
WO2002076503A1 (fr) 2000-06-20 2002-10-03 Mayo Foundation For Medical Education And Research Traitement de maladies du systeme nerveux central au moyen d'anticorps diriges contre l'acetate de glatiramere
IL148202A0 (en) * 2000-06-20 2002-09-12 Caprion Pharmaceuticals Inc Copolymers and methods of treating prion-related diseases
IL137460A0 (en) * 2000-07-24 2001-07-24 Yeda Res & Dev Identifying antigen clusters for monitoring a global state of an immune system
US20040037828A1 (en) 2002-07-09 2004-02-26 Bar-Ilan University Methods and pharmaceutical compositions for healing wounds
SV2003000753A (es) 2000-12-05 2003-06-16 Brigham & Womens Hospital Uso de polisacaridos zwitterionicos para la especifica modulacion del progreso inmunologico
KR100442122B1 (ko) * 2001-07-31 2004-07-30 한국전기연구원 영구 자석을 이용한 브러시리스 발전기
NZ533327A (en) * 2001-12-04 2006-11-30 Teva Pharma Processes for the measurement of the potency of glatiramer acetate
AU2002353486B2 (en) * 2001-12-06 2009-01-15 Yeda Research And Development Co. Ltd Vaccine and method for treatment of motor neurone diseases
WO2003059387A2 (fr) * 2001-12-21 2003-07-24 Ilex Oncology, Inc. Polytherapie pour la sclerose en plaques
CA2411786C (fr) 2002-11-13 2009-01-27 Brantford Chemicals Inc. Methode de preparation de polypeptide 1
CA2512735C (fr) 2003-01-07 2016-03-08 Yeda Research And Development Co. Ltd. Vaccin sous forme de gouttes ophtalmiques contenant un copolymere-1 destine a l'immunisation therapeutique
ZA200505733B (en) * 2003-01-21 2006-10-25 Yeda Res & Dev COP 1 for treatment of inflammatory bowel diseases
WO2004091573A1 (fr) * 2003-03-04 2004-10-28 Teva Pharmaceutical Industries, Ltd. Traitement combine a base d'acetate de glatiramer et d'alphacalcidol, destine au traitement de la sclerose en plaques
CA2520865A1 (fr) 2003-03-31 2004-10-21 The Brigham And Women's Hospital, Inc. Immunomodulateurs zwitterioniques destines au traitement de l'asthme et des allergies
EA200600877A1 (ru) * 2003-10-31 2006-12-29 Тева Фармасьютикал Индастриз, Лтд. Наночастицы для доставки лекарств
EP2301569B1 (fr) 2003-11-12 2018-05-02 Yeda Research and Development Co. Ltd. Vaccin et procédé pour le traitement des maladies neurodégénératives
CA2548310C (fr) 2003-12-09 2014-02-18 Yeda Research And Development Co. Ltd. Methode et vaccin comprenant le copolymere 1 pour le traitement de troubles psychiatriques
CA2556152A1 (fr) * 2004-02-02 2005-08-18 Mixture Sciences, Inc. Melanges de peptides a activite immunomodulatrice
MXPA06010043A (es) * 2004-03-01 2007-03-07 Peptimmune Inc Metodos y composiciones para el tratamiento de enfermedades autoinmunologicas.
AU2005218625A1 (en) * 2004-03-03 2005-09-15 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and riluzole
US20050260770A1 (en) * 2004-04-01 2005-11-24 Cohen Irun R Antigen array and diagnostic uses thereof
US7655221B2 (en) * 2004-05-07 2010-02-02 Peptimmune, Inc. Methods of treating disease with random copolymers
US20060194725A1 (en) * 2004-05-07 2006-08-31 James Rasmussen Methods of treating disease with random copolymers
MXPA06012864A (es) 2004-05-07 2007-07-18 Peptimmune Inc Metodo de tratamiento de enfermedades con copolimeros aleatorios.
EP2332569A3 (fr) 2004-06-25 2011-09-14 ID Biomedical Corporation of Quebec Compositions et procédé de traitement de troubles neurologiques
ES2572811T3 (es) * 2004-09-09 2016-06-02 Yeda Research And Development Co., Ltd. Mezclas de polipéptidos, composiciones que las contienen y procedimientos para obtener los mismos, y usos de los mismos
PT2361924E (pt) * 2004-09-09 2014-03-13 Teva Pharma Processo para a preparação de misturas de acetato de glatirâmero trifluoroacetiílico utilizando ácido bromídrico purificado
AU2005302500B2 (en) * 2004-10-29 2008-11-27 Sandoz Ag Processes for preparing glatiramer
US8324641B2 (en) * 2007-06-29 2012-12-04 Ledengin, Inc. Matrix material including an embedded dispersion of beads for a light-emitting device
ES2541780T3 (es) * 2004-11-29 2015-07-24 Yeda Research And Development Co., Ltd. Inducción de la neurogénesis y terapia con células madre en combinación con el Copolímero 1
EP1838326A4 (fr) * 2005-02-02 2009-09-30 Teva Pharma Procede de production de melanges de polypeptides par hydrogenolyse
PT1848415E (pt) * 2005-02-17 2013-06-27 Teva Pharma Terapia de combinação com acetato de glatirâmero e rasagilina para o tratamento da esclerose múltipla
US20100167983A1 (en) * 2007-10-22 2010-07-01 Teva Pharmaceutical Industries, Ltd. Combination therapy with glatiramer acetate and rasagiline for the treatment of multiple sclerosis
WO2006116602A2 (fr) * 2005-04-25 2006-11-02 Yeda Research And Development Company Marqueurs associes a l'efficacite therapeutique d'acetate de glatiramere
WO2007081975A2 (fr) * 2006-01-11 2007-07-19 Teva Pharmaceutical Industries, Ltd. Méthode de traitement de la sclérose en plaques
WO2007092451A2 (fr) 2006-02-06 2007-08-16 The Brigham And Women's Hospital, Inc. Polysaccharides zwitterioniques pour favoriser la maturation du système immunitaire et la santé
WO2007120834A2 (fr) 2006-04-13 2007-10-25 Peptimmune, Inc. Procédés de conception et de synthèse de compositions de polymères à séquence dirigée par expansion dirigée de la perméabilité épitopique
AU2007244643B2 (en) * 2006-04-28 2013-05-02 Momenta Pharmaceuticals, Inc. Methods of evaluating peptide mixtures
KR100831796B1 (ko) * 2006-05-29 2008-05-28 엘지전자 주식회사 타임 쉬프트 기능을 내장한 영상표시기기 및 그 재생 방법
JP5412280B2 (ja) 2006-06-28 2014-02-12 イエダ リサーチ アンド デベロップメント カンパニー リミテッド 加齢性黄斑変性症の治療法
DE602007003848D1 (de) * 2006-07-05 2010-01-28 Momenta Pharmaceuticals Inc Verbessertes verfahren zur herstellung von copolymer-1
AU2008265692A1 (en) 2007-06-21 2008-12-24 Momenta Pharmaceuticals, Inc. Copolymer assay
US20090029766A1 (en) * 2007-07-26 2009-01-29 Lutnick Howard W Amusement gaming access and authorization point
WO2009016643A1 (fr) * 2007-07-31 2009-02-05 Natco Pharma Limited Procédé de préparation de l'acétate de glatiramer (copolymère-1)
KR20170075026A (ko) 2007-10-16 2017-06-30 펩팀문, 인코포레이티드 에피토프의 지정 확장에 의해 지정 서열 중합체 조성물을 포함하는 백신을 설계하고 제조하는 방법
US20090124573A1 (en) 2007-11-09 2009-05-14 Sarkis Mazmanian Immunomodulating compounds and related compositions and methods
EA201070656A1 (ru) * 2007-11-28 2010-12-30 Тева Фармасьютикал Индастриз, Лтд. Способ задержки начала проявления клинически определенного рассеянного склероза
ES2449865T5 (es) 2008-04-16 2022-11-18 Momenta Pharmaceuticals Inc Análisis de composiciones de copolímeros de aminoácidos
WO2010017075A1 (fr) * 2008-08-07 2010-02-11 Sigma-Aldrich Co. Préparation de polylysine et de polyornithine de faible masse moléculaire dans un rendement élevé
CA2733500A1 (fr) * 2008-08-07 2010-02-11 Scinopharm Taiwan, Ltd. Synthese d'acetate de glatiramere
US9617313B2 (en) * 2008-12-24 2017-04-11 Synthon Bv Process for purifying a polymer mixture
WO2010115175A1 (fr) * 2009-04-03 2010-10-07 Momenta Pharmaceticals, Inc. Régulation de compositions de copolymères
WO2010140157A1 (fr) * 2009-06-04 2010-12-09 Council Of Scientific & Industrial Research Procede de preparation de copolymere-1 (cop-i), compose de medicament a base de l-alanine, l-lysine, l'acide l-glutamique et l-tyrosine pour le traitement de la sclerose en plaques
US8920373B2 (en) 2009-07-15 2014-12-30 Teva Pharmaceutical Industries, Ltd. Reduced volume formulation of glatiramer acetate and methods of administration
ATE549013T1 (de) * 2009-07-15 2012-03-15 Teva Pharma Formulierung von glatirameracetat mit verringertem volumen und verabreichungsverfahren
US8691790B2 (en) * 2009-07-27 2014-04-08 James Layne Boucher Therapy of neurological inflammatory diseases with (5'-deoxy-5'-adenosyl) cobamamide, recombinant human growth hormone, interleukins IL-1, IL-6, IL-11, epidermal growth factor, and physiotherapy
EA019998B9 (ru) 2009-08-20 2016-01-29 Йеда Рисерч Энд Дивелопмент Ко. Лтд. Терапия глатирамером ацетатом с низкой кратностью
US8377885B2 (en) 2010-01-04 2013-02-19 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
USRE49251E1 (en) 2010-01-04 2022-10-18 Mapi Pharma Ltd. Depot systems comprising glatiramer or pharmacologically acceptable salt thereof
DK3536333T3 (da) 2010-01-04 2022-10-24 Mapi Pharma Ltd Depotsystem der omfatter glatirameracetat
US20130035390A1 (en) 2010-01-13 2013-02-07 Ramot At Tel-Aviv University Ltd. Treatment of multiple sclerosis
US8759302B2 (en) * 2010-03-16 2014-06-24 Teva Pharmaceutical Industries, Ltd. Methods of treating a subject afflicted with an autoimmune disease using predictive biomarkers of clinical response to glatiramer acetate therapy in multiple sclerosis
EP2555753B1 (fr) 2010-04-07 2018-08-01 California Institute of Technology Véhicule destiné à distribuer un composé à une muqueuse et compositions, procédés et systèmes apparentés
KR20130062936A (ko) * 2010-04-27 2013-06-13 닥터 레디스 레보러터리즈 리미티드 폴리펩티드 및 그의 염의 제조
WO2011146910A1 (fr) 2010-05-20 2011-11-24 Round June L Treg spécifiques d'un antigène et compositions, procédés et systèmes associés
WO2012016042A2 (fr) 2010-07-29 2012-02-02 Dr. Reddy's Laboratories Ltd. Marqueurs de masse moléculaire à base d'acétate de glatiramer
PL2627669T3 (pl) 2010-10-11 2017-02-28 Teva Pharmaceutical Industries Ltd. Biomarkery cytokinowe jako biomarkery prognostyczne odpowiedzi klinicznej na octan glatirameru
RU2604521C2 (ru) 2011-02-14 2016-12-10 Юсв Прайвит Лимитед Сополимер-1, способы его получения и аналитические методы
EP2699317B1 (fr) * 2011-04-21 2016-08-10 Mapi Pharma Limited Pentapolymère statistique pour le traitement de maladies auto-immunes
US20140348861A1 (en) 2011-05-05 2014-11-27 National Institute Of Immunology Synthetic peptides and random copolymers for the treatment of autoimmune disorders
WO2013009864A1 (fr) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Évaluation de structure de mélanges polypeptidiques hétérogènes
WO2013009885A2 (fr) 2011-07-11 2013-01-17 Momenta Pharmaceuticals, Inc. Evaluation de diéthylamide de copolymère
JP6273200B2 (ja) 2011-07-12 2018-01-31 ザ・ブリガーム・アンド・ウーメンズ・ホスピタル・インコーポレーテッド 脂質含有ｐｓａ組成物、その単離の方法および使用の方法
US8575198B1 (en) 2011-09-07 2013-11-05 Momenta Pharmaceuticals, Inc. In-process control for the manufacture of glatiramer acetate
EP2765857A4 (fr) 2011-10-10 2015-12-09 Teva Pharma Polymorphismes de nucléotide simple utiles pour prédire une réponse clinique à l'acétate de glatiramère
WO2013139728A1 (fr) 2012-03-19 2013-09-26 Synthon Bv Test d'activité biologique de l'acétate de glatiramère à base de cellules monocytaires humaines
EP2642290A1 (fr) 2012-03-19 2013-09-25 Synthon BV Analyse de la puissance de l'acétate de glatiramère basée sur des lignées de cellules monocytaires humaines
US20140045740A1 (en) * 2012-08-13 2014-02-13 Momenta Pharmaceuticals, Inc. Analysis of glatiramer acetate
HK1213830A1 (zh) 2012-10-10 2016-07-15 Teva Pharmaceutical Industries Ltd. 用於预测醋酸格拉替雷临床反应的生物标志物
WO2014060942A2 (fr) * 2012-10-20 2014-04-24 Mahesh Kandula Compositions et méthodes pour le traitement de la sclérose en plaques et de maladies neurodégénératives
WO2014128079A1 (fr) 2013-02-19 2014-08-28 Synthon B.V. Formulation multidose d'acétate de glatiramère
RS53779B1 (sr) 2013-03-08 2015-06-30 Teva Pharmaceutical Industries Ltd. Injekcioni uređaj za višekratnu upotrebu za špric
PT2774639E (pt) 2013-03-08 2015-01-13 Teva Pharma Dispositivo injector reutilizável para seringa
CN105377308B (zh) 2013-03-14 2019-07-26 迈兰公司 醋酸格拉替雷响应生物标志物mRNA效力测定
WO2014173463A1 (fr) 2013-04-26 2014-10-30 Synthon Bv Test d'activité biologique basé sur les lignées cellulaires monocytaires humaines au moyen d'acétate de glatiramère
CA2911826C (fr) 2013-05-10 2022-08-23 California Institute Of Technology Prevention et traitement probiotiques du cancer du colon
CN103265624B (zh) * 2013-05-27 2015-04-22 成都圣诺生物制药有限公司 格拉替雷的制备方法
CN104371012A (zh) * 2013-08-12 2015-02-25 深圳翰宇药业股份有限公司 一种合成醋酸格拉替雷的方法
UY35790A (es) 2013-10-21 2015-05-29 Teva Pharma Marcadores genéticos que predicen la respuesta al acetato de glatiramer
CN105917001B (zh) 2013-10-24 2020-11-20 迈兰公司 用于评估醋酸格拉替雷制品的免疫学同一性的人类t细胞系试验
WO2015101988A1 (fr) 2013-12-31 2015-07-09 Yeda Research And Development Co. Ltd. Diagnostic du lupus érythémateux systémique à l'aide d'oligonucléotides antigènes
ES3040431T3 (en) 2014-03-12 2025-10-31 Yeda Res & Dev Reducing systemic regulatory t cell levels or activity for treatment of disease and injury of the cns
CN104844697B (zh) 2014-09-26 2018-10-23 深圳翰宇药业股份有限公司 醋酸格拉替雷的制备方法
US9155775B1 (en) 2015-01-28 2015-10-13 Teva Pharmaceutical Industries, Ltd. Process for manufacturing glatiramer acetate product
EP3265814B1 (fr) 2015-03-01 2020-11-18 Immunarray Ltd. Diagnostic du lupus érythémateux systémique à l'aide d'antigènes protéiques, peptidiques et oligonucléotidiques
US11331335B2 (en) 2015-06-10 2022-05-17 California Institute Of Technology Sepsis treatment and related compositions methods and systems
CN113637040A (zh) 2015-08-19 2021-11-12 哈佛学院院长及董事 脂化psa组合物和方法
ES2744179T3 (es) 2015-09-24 2020-02-24 Chemi Spa Análisis de la distribución de peso molecular de mezclas de polipéptidos complejas
ES2707500T3 (es) 2015-11-23 2019-04-03 Chemi Spa Análisis mediante RP-HPLC de mezclas de polipéptidos complejos
CN107522774B (zh) * 2016-06-22 2021-07-02 深圳翰宇药业股份有限公司 一种醋酸格拉替雷制备过程中哌啶残留量的实时控制方法
US12161688B2 (en) 2016-06-30 2024-12-10 Mapi Pharma Ltd Treatment of inflammatory bowel disease with long acting glatiramer and adipose-derived stem cells
US11491181B2 (en) 2016-07-15 2022-11-08 President And Fellows Of Harvard College Glycolipid compositions and methods of use
US12097292B2 (en) 2016-08-28 2024-09-24 Mapi Pharma Ltd. Process for preparing microparticles containing glatiramer acetate
JP7232752B2 (ja) 2016-08-28 2023-03-03 マピ ファーマ リミテッド 酢酸グラチラマーを含有する微小粒子を調製する方法
AU2017319728B2 (en) 2016-08-31 2024-09-05 Mapi Pharma Ltd Depot systems comprising glatiramer acetate
MX2019010174A (es) 2017-03-26 2019-10-15 Mapi Pharma Ltd Sistemas de deposito de glatiramer para el tratamiento de formas progresivas de esclerosis multiple.
CA3062964C (fr) 2017-05-15 2024-11-12 Mapi Pharma Ltd. Traitement de la sclerose en plaques avec un glatiramere a action prolongee et des cellules souches derivees du tissu adipeux
IL269893B2 (en) 2017-05-15 2023-10-01 Stem Cell Medicine Ltd Treatment of multiple sclerosis with adipose-derived stem cells
EP3765034A1 (fr) 2018-03-12 2021-01-20 Yeda Research and Development Co. Ltd Traitement d'une maladie cardiaque

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL36670A (en) * 1971-04-21 1974-09-10 Sela M Therapeutic basic copolymers of amino acids
US4444760A (en) * 1983-06-17 1984-04-24 Merck & Co., Inc. Purification and characterization of a protein fibroblast growth factor
JPS6053535A (ja) 1983-09-02 1985-03-27 Nitto Boseki Co Ltd 規則性ポリアミノ酸樹脂の製造方法
SU1182051A1 (ru) 1984-04-28 1985-09-30 Таджикский государственный университет им.В.И.Ленина Политрипептиды,обладающие энантовой селективностью в реакци х гидролиза @ -нитрофениловых эфиров карбобензокси - @ - и @ -аланина
EP0228448B1 (fr) 1985-06-18 1991-08-28 Emory University Utilisation de copolymères biologiquement actifs pour la fabrication d'un médicament pour stimuler la croissance d'un animal
DD257174A3 (de) 1985-12-20 1988-06-08 Ve Forschungszentrum Biotechno Verfahren zur herstellung der peptide z-ala-ala-lon-p-nitranilid oder z-asp-phe-ome mit metalloprotease
SU1469826A1 (ru) 1986-05-30 1995-11-20 Институт Высокомолекулярных Соединений Ан Ссср Сополимер l-лизина с l-глутаминовой кислотой, содержащий дофаминовые боковые группы, обладающий пролонгированной гипотензивной активностью и компенсаторным эффектом при геморрагическом шоке, и способ его получения
US4828706A (en) * 1988-03-07 1989-05-09 Spectrum Medical Industries Process for performing a dialysis operation
US4908404A (en) * 1988-08-22 1990-03-13 Biopolymers, Inc. Synthetic amino acid-and/or peptide-containing graft copolymers
DE8900366U1 (de) * 1989-01-13 1989-08-03 Indag Gesellschaft für Industriebedarf mbH, 69214 Eppelheim Folienbeutel
CA2009996A1 (fr) * 1989-02-17 1990-08-17 Kathleen S. Cook Procede de production de genes encodant des polymeres aleatoires d'acides amines
SU1690368A1 (ru) 1989-07-20 1995-08-20 Институт Высокомолекулярных Соединений Ан Ссср Статистические сополимеры в качестве низкотоксичных веществ, обладающих пролонгированным гипотензивным действием, и способ их получения
DE3930733A1 (de) 1989-09-14 1991-03-28 Roehm Gmbh Verfahren zur herstellung eines komplexierten arzneimittels
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
AU3130793A (en) * 1991-11-12 1993-06-15 E.I. Du Pont De Nemours And Company Collagen-like polypeptides
US5800808A (en) * 1994-05-24 1998-09-01 Veda Research And Development Co., Ltd. Copolymer-1 improvements in compositions of copolymers
US6214791B1 (en) * 1997-01-10 2001-04-10 Yeda Research And Development Co. Ltd. Treatment of multiple sclerosis through ingestion or inhalation of copolymer-1
EP0983020A1 (fr) 1997-05-06 2000-03-08 Quanta Vision, Inc. Appareil d'analyse de tissu
ATE302020T1 (de) * 2000-01-20 2005-09-15 Yeda Res & Dev Verwendung von copolymer 1- und verwandten peptiden sowie von polypeptiden und damit behandelten t-zellen zur neuroprotektiven therapie
US6936539B2 (en) * 2003-09-24 2005-08-30 Micron Technology, Inc. Antireflective coating for use during the manufacture of a semiconductor device

Also Published As

Publication number Publication date
IL113812A (en) 2000-06-29
EE03423B1 (et) 2001-06-15
PL317331A1 (en) 1997-04-01
US6939539B2 (en) 2005-09-06
HU9603243D0 (en) 1997-01-28
MD1443F1 (en) 2000-04-30
US5981589A (en) 1999-11-09
DE69525340T2 (de) 2002-09-19
NO964976L (no) 1997-01-23
SK283699B6 (sk) 2003-12-02
FI964600A0 (fi) 1996-11-15
US5800808A (en) 1998-09-01
NL300096I2 (nl) 2003-02-03
CN1310673C (zh) 2007-04-18
HK1008657A1 (en) 1999-05-14
US6054430A (en) 2000-04-25
NL300096I1 (nl) 2002-10-01
US20030064914A1 (en) 2003-04-03
US6048898A (en) 2000-04-11
FI120236B (fi) 2009-08-14
IL113812A0 (en) 1995-08-31
NO964976D0 (no) 1996-11-22
KR100403750B1 (ko) 2006-02-13
US6620847B2 (en) 2003-09-16
DE10299030I1 (de) 2003-01-23
US20040106554A1 (en) 2004-06-03
KR970703154A (ko) 1997-07-03
NO324528B1 (no) 2007-11-12
CZ341096A3 (en) 1997-06-11
MD1443G2 (ro) 2000-11-30
IL133890A0 (en) 2001-04-30
EP0762888A1 (fr) 1997-03-19
SK149396A3 (en) 1997-08-06
HUT75672A (en) 1997-05-28
US20120077754A1 (en) 2012-03-29
PL181026B1 (pl) 2001-05-31
CZ292247B6 (cs) 2003-08-13
CA2191088C (fr) 2004-09-28
ATE212857T1 (de) 2002-02-15
CA2191088A1 (fr) 1995-11-30
NZ287335A (en) 1999-02-25
US20050171286A1 (en) 2005-08-04
DE69525340D1 (de) 2002-03-21
UA62908C2 (uk) 2004-01-15
ES2172586T3 (es) 2002-10-01
JP2003105000A (ja) 2003-04-09
EE9600170A (et) 1997-06-16
CN1152874A (zh) 1997-06-25
US8367605B2 (en) 2013-02-05
HU223473B1 (hu) 2004-07-28
SI0762888T1 (en) 2002-08-31
GEP20002205B (en) 2000-08-25
US7199098B2 (en) 2007-04-03
JPH10500955A (ja) 1998-01-27
US6342476B1 (en) 2002-01-29
BRPI9507758B1 (pt) 2021-03-16
DK0762888T3 (da) 2002-05-27
JP3715600B2 (ja) 2005-11-09
WO1995031990A1 (fr) 1995-11-30
TJ392B (en) 2004-10-13
BR9507758A (pt) 1997-09-23
US20070117757A1 (en) 2007-05-24
PT762888E (pt) 2002-07-31
EP0762888A4 (fr) 1997-04-16
CN1174753C (zh) 2004-11-10
US7625861B2 (en) 2009-12-01
CN1626238A (zh) 2005-06-15
FI964600L (fi) 1996-12-05
AU2602195A (en) 1995-12-18
EP0762888B1 (fr) 2002-02-06
US6362161B1 (en) 2002-03-26

Similar Documents

Publication Publication Date Title
LU90987I2 (fr) Copaxone et ses dérivés pharmaceutiquement acceptables
EA199800357A1 (ru) Фармацевтические ангиостатические дипептидные композиции и способы их применения
LU90856I2 (fr) Uprima - apomorphine hydrochloride et ses d-riv-s pharmaceutiquement acceptables
SE9504661D0 (sv) New compounds
DZ2043A1 (fr) Nouveaux dérivés.
FR2762843B1 (fr) Nouveaux derives de cyclosporine, leur preparation et les compositions pharmaceutiques qui les contiennent
LU91673I2 (fr) "Dronédarone et ses dérivés pharmaceutiquement acceptables (MULTAQ)"
ATE218581T1 (de) Cyclosporinderivat, dessen herstellung und pharmazeutische zusammensetzung
DE69716810D1 (de) 2,3-Disubstituierte-(5,6)-heteroarylkondensierte-pyrimidin-4-one
EA199700032A1 (ru) Дезинфицирующий состав "велтолен"
ES2084149T3 (es) Conjugados de hirudinpolialquilenglicol.
NO980296L (no) Forbedrede terapeutiske midler
IL113940A (en) Synthetic peptides which are elastase inhibitors and pharmaceutical compositions for the treatment of neutrophil associated inflammatory disease containing said inhibitors
EA200000242A1 (ru) Применение фанхинона для лечения болезни альцгеймера
SE9504662D0 (sv) New compounds
CO4930269A1 (es) Composiciones farmaceuticas
TW330933B (en) Furanoeremophilane and eremophilanolide sesquiterpenes for treatment of diabetes
DE69614552D1 (de) MODIFIZIERTE ALPHA-D-GLCP-(1,2)-ALPHA-D-Glcp-(1,3)-ALPHA-D-Glcp-ANALOGE
FR2723372B1 (fr) Nouveaux derives de streptogramine, leur preparation et les compositions pharmaceutiques qui les contiennent
ES2094930T3 (es) Nueva proteina inhibidora de trombina aislada de garrapatas.
MX9500324A (es) Compuestos farmaceuticos y el uso de los mismos en el tratamiento de enfermedades neurologicas y sus etiologias sintomaticas relacionadas.